
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseases ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020 WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- …